Search Results - "WOOLFORD, J"

Changes in Body Mass Index Among Children and Adolescents During the COVID-19 Pandemic by Woolford, Susan J, Sidell, Margo, Li, Xia, Else, Veronica, Young, Deborah R, Resnicow, Ken, Koebnick, Corinna

“…The COVID-19 pandemic has been associated with weight gain among adults, but little is known about the weight of US children and adolescents. To evaluate…”
Get full text

Approaches to the diagnosis and prevention of frailty by Woolford, S. J., Sohan, O., Dennison, E. M., Cooper, C., Patel, H. P.

“…An individual who is living with frailty has impairments in homeostasis across several body systems and is more vulnerable to stressors that may ultimately…”
Get full text

Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2‑Related Factor 2 (KEAP1:NRF2) Protein–Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery by Davies, Thomas G, Wixted, William E, Coyle, Joseph E, Griffiths-Jones, Charlotte, Hearn, Keisha, McMenamin, Rachel, Norton, David, Rich, Sharna J, Richardson, Caroline, Saxty, Gordon, Willems, Henriëtte M. G, Woolford, Alison J.-A, Cottom, Joshua E, Kou, Jen-Pyng, Yonchuk, John G, Feldser, Heidi G, Sanchez, Yolanda, Foley, Joseph P, Bolognese, Brian J, Logan, Gregory, Podolin, Patricia L, Yan, Hongxing, Callahan, James F, Heightman, Tom D, Kerns, Jeffrey K

“…KEAP1 is the key regulator of the NRF2-mediated cytoprotective response, and increasingly recognized as a target for diseases involving oxidative stress…”
Get full text

Systemic inflammation and disease progression in Alzheimer disease by HOLMES, C, CUNNINGHAM, C, ZOTOVA, E, WOOLFORD, J, DEAN, C, KERR, S, CULLIFORD, D, PERRY, V. H

“…Acute and chronic systemic inflammation are characterized by the systemic production of the proinflammatory cytokine tumor necrosis factor alpha (TNF-alpha)…”
Get full text

Multi-Morbidity and Polypharmacy in Older People: Challenges and Opportunities for Clinical Practice by Aggarwal, Pritti, Woolford, Stephen J, Patel, Harnish P

“…Multi-morbidity and polypharmacy are common in older people and pose a challenge for health and social care systems, especially in the context of global…”
Get full text

Design and Synthesis of 56 Shape‐Diverse 3D Fragments by Downes, Thomas D., Jones, S. Paul, Klein, Hanna F., Wheldon, Mary C., Atobe, Masakazu, Bond, Paul S., Firth, James D., Chan, Ngai S., Waddelove, Laura, Hubbard, Roderick E., Blakemore, David C., De Fusco, Claudia, Roughley, Stephen D., Vidler, Lewis R., Whatton, Maria Ann, Woolford, Alison J.‐A., Wrigley, Gail L., O'Brien, Peter

“…Fragment‐based drug discovery is now widely adopted for lead generation in the pharmaceutical industry. However, fragment screening collections are often…”
Get full text

Conceptualizing Trust and Distrust as Alternative Stable States: Lessons from the Flint Water Crisis by Hamm, J A, Carrera, J S, Van Fossen, J A, Key, K D, Woolford, S J, Bailey, S B, McKay, A S, Evans, L B, Calhoun, K D

“…Despite the universally recognized importance of fostering trust and avoiding distrust in governance relationships, there remains considerable debate on core…”
Get full text

Structure–Activity and Structure–Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2‑Related Factor 2 (KEAP1/NRF2) Protein–Protein Interaction by Heightman, Tom D, Callahan, James F, Chiarparin, Elisabetta, Coyle, Joseph E, Griffiths-Jones, Charlotte, Lakdawala, Ami S, McMenamin, Rachel, Mortenson, Paul N, Norton, David, Peakman, Torren M, Rich, Sharna J, Richardson, Caroline, Rumsey, William L, Sanchez, Yolanda, Saxty, Gordon, Willems, Henriëtte M. G, Wolfe, Lawrence, Woolford, Alison J.-A, Wu, Zining, Yan, Hongxing, Kerns, Jeffrey K, Davies, Thomas G

“…The KEAP1–NRF2-mediated cytoprotective response plays a key role in cellular homoeostasis. Insufficient NRF2 signaling during chronic oxidative stress may be…”
Get full text

Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP by Chessari, Gianni, Buck, Ildiko M, Day, James E. H, Day, Philip J, Iqbal, Aman, Johnson, Christopher N, Lewis, Edward J, Martins, Vanessa, Miller, Darcey, Reader, Michael, Rees, David C, Rich, Sharna J, Tamanini, Emiliano, Vitorino, Marc, Ward, George A, Williams, Pamela A, Williams, Glyn, Wilsher, Nicola E, Woolford, Alison J.-A

“…Inhibitor of apoptosis proteins (IAPs) are important regulators of apoptosis and pro-survival signaling pathways whose deregulation is often associated with…”
Get full text

Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency by Murray, Christopher W, Carr, Maria G, Callaghan, Owen, Chessari, Gianni, Congreve, Miles, Cowan, Suzanna, Coyle, Joseph E, Downham, Robert, Figueroa, Eva, Frederickson, Martyn, Graham, Brent, McMenamin, Rachel, O’Brien, M. Alistair, Patel, Sahil, Phillips, Theresa R, Williams, Glyn, Woodhead, Andrew J, Woolford, Alison J.-A

“…Inhibitors of the chaperone Hsp90 are potentially useful as chemotherapeutic agents in cancer. This paper describes an application of fragment screening to…”
Get full text

Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design by Woodhead, Andrew J, Angove, Hayley, Carr, Maria G, Chessari, Gianni, Congreve, Miles, Coyle, Joseph E, Cosme, Jose, Graham, Brent, Day, Philip J, Downham, Robert, Fazal, Lynsey, Feltell, Ruth, Figueroa, Eva, Frederickson, Martyn, Lewis, Jonathan, McMenamin, Rachel, Murray, Christopher W, O’Brien, M. Alistair, Parra, Lina, Patel, Sahil, Phillips, Theresa, Rees, David C, Rich, Sharna, Smith, Donna-Michelle, Trewartha, Gary, Vinkovic, Mladen, Williams, Brian, Woolford, Alison J.-A

“…Inhibitors of the molecular chaperone heat shock protein 90 (Hsp90) are currently generating significant interest in clinical development as potential…”
Get full text

Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2 by Heightman, Tom D, Berdini, Valerio, Braithwaite, Hannah, Buck, Ildiko M, Cassidy, Megan, Castro, Juan, Courtin, Aurélie, Day, James E. H, East, Charlotte, Fazal, Lynsey, Graham, Brent, Griffiths-Jones, Charlotte M, Lyons, John F, Martins, Vanessa, Muench, Sandra, Munck, Joanne M, Norton, David, O’Reilly, Marc, Palmer, Nick, Pathuri, Puja, Reader, Michael, Rees, David C, Rich, Sharna J, Richardson, Caroline, Saini, Harpreet, Thompson, Neil T, Wallis, Nicola G, Walton, Hugh, Wilsher, Nicola E, Woolford, Alison J.-A, Cooke, Michael, Cousin, David, Onions, Stuart, Shannon, Jonathan, Watts, John, Murray, Christopher W

“…Aberrant activation of the MAPK pathway drives cell proliferation in multiple cancers. Inhibitors of BRAF and MEK kinases are approved for the treatment of…”
Get full text

COVID-19 and associations with frailty and multimorbidity: a prospective analysis of UK Biobank participants by Woolford, S. J., D’Angelo, S., Curtis, E. M., Parsons, C. M., Ward, K. A., Dennison, E. M., Patel, H. P., Cooper, C., Harvey, N. C.

“…Background Frailty and multimorbidity have been suggested as risk factors for severe COVID-19 disease. Aims We investigated, in the UK Biobank, whether frailty…”
Get full text

Fragment-Guided Discovery of Pyrazole Carboxylic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2 Related Factor 2 (KEAP1:NRF2) Protein−Protein Interaction by Norton, David, Bonnette, William G, Callahan, James F, Carr, Maria G, Griffiths-Jones, Charlotte M, Heightman, Tom D, Kerns, Jeffrey K, Nie, Hong, Rich, Sharna J, Richardson, Caroline, Rumsey, William, Sanchez, Yolanda, Verdonk, Marcel L, Willems, Henriëtte M. G, Wixted, William E, Woolford, Alison J.-A, Wu, Zining, Davies, Thomas G

“…The NRF2-mediated cytoprotective response is central to cellular homoeostasis, and there is increasing interest in developing small-molecule activators of this…”
Get full text

Sleep Duration Predicts Cardiometabolic Risk in Obese Adolescents by IglayReger, Heidi B., PhD, Peterson, Mark D., PhD, MS, Liu, Dongmei, PhD, Parker, Christine A., MS, Woolford, Susan J., MPH, MD, (Sallinen) Gafka, Bethany J., PhD, Hassan, Fauziya, MD, MS, Gordon, Paul M., PhD, MPH

“…Objective To examine the independent contributions of objectively measured sleep duration and fragmentation on cardiometabolic risk accumulation in free-living…”
Get full text

Identification of N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design by Wyatt, Paul G, Woodhead, Andrew J, Berdini, Valerio, Boulstridge, John A, Carr, Maria G, Cross, David M, Davis, Deborah J, Devine, Lindsay A, Early, Theresa R, Feltell, Ruth E, Lewis, E. Jonathan, McMenamin, Rachel L, Navarro, Eva F, O’Brien, Michael A, O’Reilly, Marc, Reule, Matthias, Saxty, Gordon, Seavers, Lisa C. A, Smith, Donna-Michelle, Squires, Matt S, Trewartha, Gary, Walker, Margaret T, Woolford, Alison J.-A

“…The application of fragment-based screening techniques to cyclin dependent kinase 2 (CDK2) identified multiple (>30) efficient, synthetically tractable small…”
Get full text

201 Challenges Encountered and Lessons Learned from Developing and Implementing the Michigan Research Engaging the Academy and Community in Health (M-REACH) Platform by Vereen, Donald, McKay, Athena, Veinot, Tiffany, Piechowski, Patricia, Allen, Polly Gipson, Woolford, Susan J., Bailey, Sarah

“…OBJECTIVES/GOALS: Communities of color often report that their concerns are ignored and desire a means to facilitate effective community-academic engagement,…”
Get full text

Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor by Tamanini, Emiliano, Miyamura, Shin, Buck, Ildiko M., Cons, Benjamin D., Dawson, Lee, East, Charlotte, Futamura, Takashi, Goto, Shintaro, Griffiths-Jones, Charlotte, Hashimoto, Tetsuya, Heightman, Tom D., Ishikawa, Shunpei, Ito, Hideki, Kaneko, Yosuke, Kawato, Tatsuya, Kondo, Kazumi, Kurihara, Naoki, McCarthy, James M., Mori, Yukiko, Nagase, Tsuyoshi, Nakaishi, Yuichiro, Reeks, Judith, Sato, Akimasa, Schöpf, Patrick, Tai, Kuninori, Tamai, Taichi, Tisi, Dominic, Woolford, Alison J.-A.

“…Fragment-based ligand discovery was successfully applied to histone deacetylase HDAC2. In addition to the anticipated hydroxamic acid- and benzamide-based…”
Get full text

Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) by Woolford, Alison J.-A, Day, Philip J, Bénéton, Véronique, Berdini, Valerio, Coyle, Joseph E, Dudit, Yann, Grondin, Pascal, Huet, Pascal, Lee, Lydia Y. W, Manas, Eric S, McMenamin, Rachel L, Murray, Christopher W, Page, Lee W, Patel, Vipulkumar K, Potvain, Florent, Rich, Sharna J, Sang, Yingxia, Somers, Don O, Trottet, Lionel, Wan, Zehong, Zhang, Xiaomin

“…Lp-PLA2 has been explored as a target for a number of inflammation associated diseases, including cardiovascular disease and dementia. This article describes…”
Get full text

Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X‑ray Fragment Screening by Woolford, Alison J.-A, Pero, Joseph E, Aravapalli, Sridhar, Berdini, Valerio, Coyle, Joseph E, Day, Philip J, Dodson, Andrew M, Grondin, Pascal, Holding, Finn P, Lee, Lydia Y. W, Li, Peng, Manas, Eric S, Marino, Joseph, Martin, Agnes C. L, McCleland, Brent W, McMenamin, Rachel L, Murray, Christopher W, Neipp, Christopher E, Page, Lee W, Patel, Vipulkumar K, Potvain, Florent, Rich, Sharna, Rivero, Ralph A, Smith, Kirsten, Somers, Donald O, Trottet, Lionel, Velagaleti, Ranganadh, Williams, Glyn, Xie, Ren

“…Elevated levels of human lipoprotein-associated phospholipase A2 (Lp-PLA2) are associated with cardiovascular disease and dementia. A fragment screen was…”
Get full text